|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01801 INNOVENT BIO
Nominal 
38.500 -0.300 (-0.773%) Profitability Analysis
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| ROAA (%) | -5.379% | -12.883% | -19.436% | -10.474% | -25.780% |
| ROAE (%) | -8.839% | -20.695% | -28.558% | -14.752% | -38.432% |
| Return on Capital Employed (%) | -6.365% | -15.467% | -20.682% | -9.647% | -27.800% |
Margin Analysis
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Gross Profit Margin (%) | 81.691% | 79.567% | 88.165% | 89.912% | 88.079% |
| EBITDA Margin (%) | -20.106% | -45.662% | -61.033% | -21.355% | -161.678% |
| Pre-tax Profit Margin (%) | -18.440% | -47.636% | -61.871% | -22.340% | -164.192% |
| Net Profit Margin (%) | -16.563% | -47.829% | -63.909% | -25.975% | -164.192% |
Liquidity Analysis
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Current Ratio (X) | 2.999 X | 3.288 X | 3.787 X | 6.371 X | 5.228 X |
| Quick Ratio (X) | 2.783 X | 2.880 X | 3.345 X | 5.896 X | 4.884 X |
Leverage Analysis
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Total Liabilities / Total Assets(%) | 39.267% | 38.996% | 36.404% | 25.815% | 34.222% |
| Total Debt / Total Assets (%) | 17.552% | 18.355% | 15.372% | 10.195% | 11.964% |
| Net Debt / Total Assets (%) | -31.180% | -33.739% | -36.200% | -55.406% | -46.574% |
| Total Debt / Shareholders' Funds (%) | 28.900% | 30.089% | 24.171% | 13.743% | 18.189% |
| Long Term Debt / Shareholders' Funds (%) | 19.159% | 21.567% | 20.422% | 10.654% | 17.505% |
| Net Debt / Shareholders' Funds (%) | -51.339% | -55.306% | -56.921% | -74.686% | -70.804% |
| Net Cash / (Debt) ($) | 6.432B | 5.934B | 5.880B | 6.557B | 3.368B |
| Net Cash / (Debt) per share ($) | 3.966 | 3.867 | 4.022 | 4.674 | 2.667 |
| Total Debt / Capital Employed (%) | 22.417% | 22.914% | 18.925% | 11.659% | 13.982% |
| Interest Coverage Ratio (X) | N/A | N/A | N/A | N/A | N/A |
Efficiency Analysis
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Inventory Turnover (Day) | 384.986 Day | 544.197 Day | 741.394 Day | 500.892 Day | 620.694 Day |
| Receivables Turnover (Day) | 46.497 Day | 61.830 Day | 61.711 Day | 34.338 Day | 86.362 Day |
| Payables Turnover (Day) | 20.531 Day | 20.855 Day | 13.493 Day | 9.728 Day | 22.143 Day |
| Remarks: | Real time quote last updated: 21/11/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -392,620 |
| %Change | 182.158% |
| EPS / (LPS) | RMB -0.240 |
| NBV Per Share (¥) | RMB 7.631 |